endosome-lysosome associated apoptosis and autophagy regulator 1Genealiases: EIG121 · KIAA1324
Q-omics provides the consensus-scored ELAPOR1 profile across patient tissues and cancer cell-line models. ELAPOR1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ELAPOR1 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, ELAPOR1 protein abundance shows 25,725 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRP, THCA, and BRCA as cancer lineages where ELAPOR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ELAPOR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ELAPOR1 survival associations across molecular data types. ELAPOR1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ELAPOR1 RNA expression–survival associations across cancer types. High ELAPOR1 expression shows unfavorable associations in KIRP and MESO, but favorable associations in UCEC, SKCM, OV and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ELAPOR1 RNA expression.
This table summarizes ELAPOR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 8. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for ELAPOR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ELAPOR1 shows lower tumor expression in THCA, KICH and LUSC and higher tumor expression in KIRC, LIHC and KIRP. The THCA box plot shows higher ELAPOR1 RNA expression in normal versus tumor tissue (log2 FC = −3.374, t-test p < 0.001).
This table shows molecular features associated with ELAPOR1 in patient tissues and cancer cell lines. In patient samples, ELAPOR1 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, ELAPOR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BREAST.
